Pharmacogenetics of warfarin and healthcare costs - Real-world data analysis.
Jaakko LähteenmäkiAnna-Leena VuorinenMika LehtoMikko NiemiMarkus M ForsbergPublished in: Pharmacoepidemiology and drug safety (2022)
The difference in the costs of bleeding-related hospitalization between genetically sensitive and normal warfarin responders may justify genotype-guided warfarin dosing. Further studies with larger sample sizes would be needed to verify the result.